

**Short CV: Prof. Peter Scanlon MD FRCP DCH DRCOG DO FRCOphth FHEA**

**Nationality** British  
Department of Ophthalmology, Gloucestershire Hospitals NHS Foundation trust, GDRRG Office above Oakley Ward, Centre Block, Cheltenham General Hospital, Sandford Road, Cheltenham, GL53 7AN.

**Telephone** 03004 222851

**Email** [peter.scanlon@glos.nhs.uk](mailto:peter.scanlon@glos.nhs.uk)

**Current Appointments:**

1. Clinical Director for the English National Diabetic Retinopathy Screening Programme;
2. Consultant Ophthalmologist, Gloucestershire Eye Unit;
3. Consultant Ophthalmologist, Oxford Eye Hospital;
4. Senior Research Fellow, Harris Manchester College, University of Oxford;
5. Honorary Senior Research Fellow, Department of Neuroscience, University of Oxford;
6. Honorary Associate Professor, University of Warwick Medical School;
7. Visiting Professor of Medical Ophthalmology at the University of Bedfordshire and Hertfordshire Postgraduate Medical School.

**Publications since 2000 in peer reviewed journals:**

1. Scanlon P. Screening for diabetic retinopathy by digital imaging photography and technician ophthalmoscopy. *Diabetes Technology and Therapeutics*, 2000; **2** (2): 283-7
2. Scanlon P. Digital retinal photography in diabetic eye screening. *Diabetes Technology and Therapeutics*, 2001; **3** (2): 187-191
3. Scanlon, P. H., Malhotra, R., Thomas, G., Foy, C., Kirkpatrick, J. N., Lewis-Barned, N., Harney, B. & Aldington, S. J. The effectiveness of screening for diabetic retinopathy by digital imaging photography and technician ophthalmoscopy. *Diabetic Medicine*. 2003; **20** (6), 467-474.
4. Scanlon PH, Malhotra R, Greenwood RH, Aldington SJ, Foy C, Flatman M, et al. Comparison of two reference standards in validating two field mydriatic digital photography as a method of screening for diabetic retinopathy. *Br J Ophthalmol* 2003;**87**(10):1258-63.
5. Harding S, Greenwood R, Aldington S, Gibson J, Owens D, Taylor R, Kohner E, Scanlon P, Leese G. Grading and disease management in national screening for diabetic retinopathy in England and Wales. *Diabet Med* 2003;**20** (12):965-71.
6. Garvican, L. & Scanlon, P. H. A pilot quality assurance scheme for diabetic retinopathy risk reduction programmes. *Diabet Med* 2004; **21** (10), 1066-1074.
7. Scanlon PH, Carter S, Foy C, Ratiram D, Harney B. An evaluation of the change in activity and workload arising from diabetic ophthalmology referrals following the introduction of a community based digital retinal photographic screening programme. *Br J Ophthalmol* 2005; **89**(8): 971-5.
8. Scanlon PH, Foy C, Malhotra R, Aldington SJ. The influence of age, duration of diabetes, cataract, and pupil size on image quality in digital photographic retinal screening. *Diabetes Care* 2005; **28**(10): 2448-53.
9. Scanlon PH, Martin ML, Bailey C, Johnson E, Hykin P, Keightley S. Reported symptoms and quality-of-life impacts in patients having laser treatment for sight-threatening diabetic retinopathy. *Diabetic Medicine* 2006; **23**(1):60-6.
10. Atan D, Foy C and Scanlon PH, Reply to study by Conrath et al, "Evaluation of the effect of JPEG and JPEG2000 image compression on the detection of diabetic retinopathy" letter. *Eye*. 2008;**22**(3):471; author reply 473
11. Scanlon PH. The English national screening programme for sight-threatening diabetic retinopathy. *J Med Screen* 2008;**15**(1):1-4.
12. Scanlon PH, Foy C, Chen FK. Visual Acuity Measurement and Ocular Co-Morbidity in Diabetic Retinopathy Screening. *Br J Ophthalmol* 2008; **92**(6):775-8
13. Scanlon PH, Carter S, Foy C, Husband R, Abbas J and Bachmann MO. Diabetic Retinopathy and Socio-Economic Deprivation in Gloucestershire. *J Med Screen* 2008;**15**(3): 118-21
14. Taylor DJ, Goatman KA, Gregory A, Histed MG, Martin CN, Warburton TJ and Scanlon PH. Image quality standardisation for diabetic retinopathy screening. *Expert Review of Ophthalmology*, 2009; **4** (5): 469-476

15. West SD, Groves DC, Lipinski HJ, Nicoll DJ, Mason RH, Scanlon PH, et al. The prevalence of retinopathy in men with Type 2 diabetes and obstructive sleep apnoea. *Diabet Med* 2010;27(4):423-30.
16. Scanlon, P. H. (2010). "Why do patients still require surgery for the late complications of Proliferative Diabetic Retinopathy?" *Eye (Lond)* **24**(3): 435-440.
17. Sallam A, Scanlon PH, Stratton IM, Jones V, Martin CN, Brelen M, Johnston RL. Agreement and reasons for disagreement between photographic and hospital biomicroscopy grading of diabetic retinopathy. *Diabet Med*. 2011 28(6): 741-746
18. Chu, C. Scanlon PH. Vitamin B 12 deficiency optic neuropathy detected by asymptomatic screening. *BMJ Case Reports* 2011; doi:10.1136/bcr.02.2011.3823
19. Hadley G, Earnshaw JJ, Stratton I, Sykes J, Scanlon PH. A Potential Pathway for Managing Diabetic Patients with Arterial Emboli Detected by Retinal Screening. *Eur J Vasc Endovasc Surg*. 2011. Aug;42(2):153-7.
20. Scanlon PH. The preferences of people with diabetes for diabetic retinopathy screening. *Diabet Med*. 2012 Jul;29(7):836-7.
21. Simó R, Hernández C; on behalf of the European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR)\*. Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. *Br J Ophthalmol*. 2012 Oct;96(10):1285-1290.
22. Sachdeva A, Stratton IM, Unwin J, Moreton R and Scanlon PH. Diabetic retinopathy screening: Study to determine risk factors for non-attendance. *Diabetes & Primary Care*. 2012; 14 (5): 308-16.
23. Ross AH, Donachie PH, Sallam A, Stratton IM, Mohamed Q, Scanlon PH, Kirkpatrick JN, Johnston RL. Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab? *Eye (Lond)*. 2013 Jan;27(1):56-64.
24. Stratton IM, Aldington SJ, Taylor DJ, Adler AI, Scanlon PH. A simple risk stratification for time to development of sight threatening diabetic retinopathy. *Diabetes Care*. 2013 Mar;36(3):580-5.
25. Scanlon P.H. Stratton I.M. Histed. M. Chave S.J. Aldington S.J. The influence of background diabetic retinopathy in the second eye on rates of progression of diabetic retinopathy between 2005 and 2010. *Acta Ophthalmol*. 2013 Apr 1. doi: 10.1111/aos.12074. [Epub ahead of print]
26. Scanlon P.H. Aldington S.J. Stratton I.M. Delay in Diabetic Retinopathy Screening Increases the Rate of Detection of Referable Diabetic Retinopathy. Accepted by *Diabetic Medicine* on 25<sup>th</sup> July 2013. Article first published online: 17 OCT 2013 DOI: 10.1111/dme.12313
27. Keenan, T. D., et al. (2013). "United Kingdom National Ophthalmology Database Study: Diabetic Retinopathy; Report 1: prevalence of centre-involving diabetic macular oedema and other grades of maculopathy and retinopathy in hospital eye services." *Eye (Lond)* **27**(12): 1397-1404.
28. Scanlon, P. H., et al. (2013). "Updating Diabetic Retinopathy screening lists using automatic extraction from GP patient records." *J Med Screen* **20**(3): 111-117.
29. Scanlon, P. H., et al. (2013). "Epidemiological issues in diabetic retinopathy." *Middle East Afr J Ophthalmol* **20**(4): 293-300.
30. Healy, R., Sallam, A., Jones, V., Donachie, P.H., Scanlon, P.H., Stratton, I.M., and Johnston, R.L., Agreement between photographic screening and hospital biomicroscopy grading of diabetic retinopathy and maculopathy. *Eur J Ophthalmol*, 2013: epub
31. Simó R, Hernández C; on behalf of the European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR)\*. Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives"(Trends Endocrinol Metab 2014;25:23-33)

**Posters since 2005:** 27 posters including the poster Award at the November 2011 2nd International Digital Healthcare Conference at the University of Warwick for a poster entitled 'The English National Screening Programme For Sight Threatening Diabetic Retinopathy' by Scanlon P.H. Aldington S.J.

#### **Books:**

Practical Manual of Diabetic Retinopathy Management', Scanlon PH, Wilkinson CP, Aldington SJ, Matthews DR. Wiley Blackwell. January 2009.

#### **Chapters for books:**

1. Diabetic Retinopathy in Textbook of Diabetes: A Clinical Approach. 2010. Richard Holt, Barry Goldstein, Clive Cockram and Allan Flyvbjerg. Wiley Blackwell

2. Diabetic Retinopathy Screening – Progress or lack of Progress in Visual Dysfunction In Diabetes. 2010. Joyce Tombran-Tink, Ph.D. Colin J. Barnstable, D.Phil. and Thomas W. Gardner, M.D., M.S. Humana Press (An Imprint of Springer)
3. Diabetic Retinopathy . Journal: Medicine. 1 April 2010. Issue: Diabetes II Volume 38 Issue 12. Chapter Editors: Simon Heller and Sean Dinneen. Medicine Publishing (An Imprint of Elsevier)
4. Title of Case study for book : Deterioration in vision after commencing insulin treatment (the early worsening phenomenon). HbA1c in diabetes -Case studies in IFCC units. SE Manley, IM Stratton, SC Gough. Wiley Blackwell. March 2010
5. The systematic DR screening in England for 2 million people with diabetes'. Teleophthalmology in Practice. 2<sup>nd</sup> Ed. Prof K Yogesan, Lions Eye Institute, Australia. Prof Len Goldschmidt Stanford USA and Dr Jorge Cuadros Berkeley USA. Springer. 2012.
6. 'Diabetic Eye Disease'. Oxford Handbook of Endocrinology and Diabetes. 3rd Edition: John Wass, Katherine Owen; Oxford University Press. 2012.

### Grants Held in the last 3 years:

PROJECT: Diabetes Research Network (DRN) Writing Group  
(Joint applicant with SP Harding)

Funding body: Diabetes Research Network (DRN)

Total awarded: £5,000

Duration: 2 years

End date: December 2010 – was extended until May 2013.

PROJECT: 'Understanding factors leading to low uptake of diabetic retinopathy screening in Primary Care' (joint lead applicant with Dr Jackie Sturt from Warwick Medical School.)

Funding body: Research for Patient Benefit Programme

Total awarded: £219,885

Duration: 18 months – commenced November 2010

End date: Was completed in November 2012

PROJECT: Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening (lead applicant)

Funding body: HTA

Total awarded: £394,696

Duration: 24 months

Start Date: 1<sup>st</sup> May 2012

PROJECT: European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR)  
(Collaborative first clinical trial using eye drops for treatment of the early stages of DR) (co-applicant)

Funding body: European Commission (Framework 7)

Total awarded: Euros 277,420

Duration: 24 months

Start Date: September 2012

PROJECT: Prediction of retinopathy risk in a cohort of young people with type 1 diabetes (co-applicant)

Funding body: Diabetes UK

Total awarded: £ 14,169

Duration: 12 months

Start Date: February 2012